Skip to main content
Journal cover image

Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.

Publication ,  Journal Article
Weissler, EH; Annapureddy, A; Wang, Y; Secemsky, EA; Shishehbor, MH; Mena-Hurtado, C; Jelani, Q-U-A; Aronow, HD; Tsai, TT; Patel, MR; Jones, WS ...
Published in: Am Heart J
March 2021

BACKGROUND: The connection between paclitaxel-coated devices (PCD) use during peripheral vascular interventions (PVI) and mortality is debated. We aimed to analyze patterns of PCD use and the safety and effectiveness of PCD use in the superficial femoral and/or popliteal arteries. METHODS: Patients undergoing PVI of femoropopliteal lesions with and without PCD between January 1, 2015 and June 30, 2017 were compared using the American College of Cardiology's National Cardiovascular Data Registry PVI Registry. Outcomes were derived from Centers for Medicare & Medicaid claims data. The primary outcome was all-cause mortality at 6-, 12-, and 24-months following PVI. Inverse probability weighting and frailty models were used to assess the differences between groups. The analysis was IRB-approved. RESULTS: In the overall cohort consisting of 6,302 femoropopliteal PVIs, PCD-PVI patients were more likely to be treated for claudication (63.5% vs 51.3%, P< .001), less likely to have a chronic total occlusion (24.6% vs 34.7%, P < .001), and more likely to be treated in certain geographic and practice settings. In the analytic cohort consisting of 1,666 femoropopliteal PVIs with linked claims outcomes (888 PCD-PVI, 53.3%), unadjusted rates of all outcomes were lower in PCD-PVI patients. After adjustment, there were no significant differences in mortality following PCD-PVI versus non-PCD PVI at 1 year (adjusted RR 0.78, 95% CI 0.60-1.01, P= .055) or 2 years (aRR 0.98, 95% CI 0.77-1.24, P= .844). CONCLUSION: There were significant differences between the patients in whom and settings in which PCD-PVI was versus was not used. PCD-PVI was not associated with an increased risk of 2-year mortality in real-world use.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2021

Volume

233

Start / End Page

59 / 67

Location

United States

Related Subject Headings

  • United States
  • Time Factors
  • Registries
  • Popliteal Artery
  • Peripheral Arterial Disease
  • Paclitaxel
  • Male
  • Humans
  • Femoral Artery
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weissler, E. H., Annapureddy, A., Wang, Y., Secemsky, E. A., Shishehbor, M. H., Mena-Hurtado, C., … Jones, W. S. (2021). Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. Am Heart J, 233, 59–67. https://doi.org/10.1016/j.ahj.2020.12.004
Weissler, Elizabeth Hope, Amarnath Annapureddy, Yongfei Wang, Eric A. Secemsky, Mehdi H. Shishehbor, Carlos Mena-Hurtado, Qurat-Ul-Ain Jelani, et al. “Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.Am Heart J 233 (March 2021): 59–67. https://doi.org/10.1016/j.ahj.2020.12.004.
Weissler EH, Annapureddy A, Wang Y, Secemsky EA, Shishehbor MH, Mena-Hurtado C, et al. Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. Am Heart J. 2021 Mar;233:59–67.
Weissler, Elizabeth Hope, et al. “Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.Am Heart J, vol. 233, Mar. 2021, pp. 59–67. Pubmed, doi:10.1016/j.ahj.2020.12.004.
Weissler EH, Annapureddy A, Wang Y, Secemsky EA, Shishehbor MH, Mena-Hurtado C, Jelani Q-U-A, Aronow HD, Tsai TT, Patel MR, Curtis JP, Jones WS. Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. Am Heart J. 2021 Mar;233:59–67.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2021

Volume

233

Start / End Page

59 / 67

Location

United States

Related Subject Headings

  • United States
  • Time Factors
  • Registries
  • Popliteal Artery
  • Peripheral Arterial Disease
  • Paclitaxel
  • Male
  • Humans
  • Femoral Artery
  • Female